StockData
Theriva Biologics, Inc. logo

Theriva Biologics, Inc. (TOVX) stock

TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.14+0.00 (+2.86%)

Close on Nov 18, 2026Market cap $6.61MP/E –Yield –

Theriva Biologics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Theriva Biologics's operating cash flow for the twelve months ending Jun 30, 2026 was -$12.74M. For fiscal 2025 it was -$16.67M. The highest annual figure on record is -$1.15M in fiscal 2010.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$16.67M–
FY2024Dec 31, 2024-$16.94M–
FY2023Dec 31, 2023-$19.00M–
FY2022Dec 31, 2022-$19.08M–
FY2021Dec 31, 2021-$12.89M–
FY2020Dec 31, 2020-$12.17M–
FY2019Dec 31, 2019-$13.87M–
FY2018Dec 31, 2018-$17.28M–
FY2017Dec 31, 2017-$20.20M–
FY2016Dec 31, 2016-$27.90M–
FY2015Dec 31, 2015-$38.89M–
FY2014Dec 31, 2014-$16.08M–
FY2013Dec 31, 2013-$7.72M–
FY2012Dec 31, 2012-$8.92M–
FY2011Dec 31, 2011-$2.88M–
FY2010Dec 31, 2010-$1.15M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.09M–
Q1 FY2026Mar 31, 2026-$2.46M–
Q4 FY2025Dec 31, 2025-$2.88M–
Q3 FY2025Sep 30, 2025-$4.32M–
Q2 FY2025Jun 30, 2025-$4.71M–
Q1 FY2025Mar 31, 2025-$4.76M–
Q4 FY2024Dec 31, 2024-$4.69M–
Q3 FY2024Sep 30, 2024-$3.91M–
Q2 FY2024Jun 30, 2024-$3.45M–
Q1 FY2024Mar 31, 2024-$4.88M–
Q4 FY2023Dec 31, 2023-$6.54M–
Q3 FY2023Sep 30, 2023-$2.95M–
Q2 FY2023Jun 30, 2023-$3.89M–
Q1 FY2023Mar 31, 2023-$5.61M–
Q4 FY2022Dec 31, 2022-$5.37M–
Q3 FY2022Sep 30, 2022-$4.46M–
Q2 FY2022Jun 30, 2022-$4.36M–
Q1 FY2022Mar 31, 2022-$4.90M–
Q4 FY2021Dec 31, 2021-$4.81M–
Q3 FY2021Sep 30, 2021-$2.16M–
Q2 FY2021Jun 30, 2021-$2.60M–
Q1 FY2021Mar 31, 2021-$3.33M–
Q4 FY2020Dec 31, 2020-$3.13M–
Q3 FY2020Sep 30, 2020-$2.05M–
Q2 FY2020Jun 30, 2020-$2.03M–
Q1 FY2020Mar 31, 2020-$4.96M–
Q4 FY2019Dec 31, 2019-$3.61M–
Q3 FY2019Sep 30, 2019-$3.06M–
Q2 FY2019Jun 30, 2019-$2.98M–
Q1 FY2019Mar 31, 2019-$4.22M–
Q4 FY2018Dec 31, 2018-$3.29M–
Q3 FY2018Sep 30, 2018-$3.60M–
Q2 FY2018Jun 30, 2018-$4.31M–
Q1 FY2018Mar 31, 2018-$6.08M–
Q4 FY2017Dec 31, 2017-$3.93M–
Q3 FY2017Sep 30, 2017-$4.52M–
Q2 FY2017Jun 30, 2017-$5.74M–
Q1 FY2017Mar 31, 2017-$6.01M–
Q4 FY2016Dec 31, 2016-$10.38M–
Q3 FY2016Sep 30, 2016-$5.98M–

More Theriva Biologics figures

See a number that looks wrong?